Preparation and characterization of diaspirin cross-linked hemoglobin solutions for preclinical studies.
During 1990 and 1991 the capability for repetitive, consecutive production of DCLHb solution to meet a rigorous and complete set of product criteria was demonstrated. In addition, through periodic monitoring of product stored under controlled conditions, the stability of all lots of DCLHb solution during frozen storage was demonstrated for more than a year. In this way, assurance was provided that the DCLHb solution used in preclinical testing met all product criteria throughout the biological testing period.
Nelson
D
D
Blood Substitutes Program, Baxter Healthcare Corporation, Los Angeles, CA.
Azari
M
M
Brown
R
R
Burhop
K
K
Bush
S
S
Catarello
J
J
Chuang
H
H
Downing
C
C
Estep
T
T
Loewen
A
A
D001241:Aspirin / Q000031:analogs & derivatives; D001802:Blood Substitutes / Q000302:isolation & purification*; D003432:Cross-Linking Reagents; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D006454:Hemoglobins / Q000302:isolation & purification*; D006801:Humans; D012996:Solutions
D001802:Blood Substitutes; D003432:Cross-Linking Reagents; D006454:Hemoglobins; D012996:Solutions; C030830:succinyldisalicylic acid; D001241:Aspirin